CN105037533A - Arsenic-hemoglobin chelate as well as preparation method and application thereof - Google Patents
Arsenic-hemoglobin chelate as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN105037533A CN105037533A CN201510413076.1A CN201510413076A CN105037533A CN 105037533 A CN105037533 A CN 105037533A CN 201510413076 A CN201510413076 A CN 201510413076A CN 105037533 A CN105037533 A CN 105037533A
- Authority
- CN
- China
- Prior art keywords
- arsenic
- oxyphorase
- inner complex
- sample
- chromatography column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000013522 chelant Substances 0.000 title abstract description 8
- 229910052785 arsenic Inorganic materials 0.000 claims abstract description 145
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims abstract description 135
- 238000001514 detection method Methods 0.000 claims abstract description 25
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 100
- 239000013024 dilution buffer Substances 0.000 claims description 76
- 102000004190 Enzymes Human genes 0.000 claims description 58
- 108090000790 Enzymes Proteins 0.000 claims description 58
- 210000004369 blood Anatomy 0.000 claims description 58
- 239000008280 blood Substances 0.000 claims description 57
- 238000004587 chromatography analysis Methods 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 239000000872 buffer Substances 0.000 claims description 29
- 238000001962 electrophoresis Methods 0.000 claims description 28
- 238000000746 purification Methods 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 239000003292 glue Substances 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 24
- 238000010790 dilution Methods 0.000 claims description 20
- 239000012895 dilution Substances 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 20
- 238000000502 dialysis Methods 0.000 claims description 17
- 230000001900 immune effect Effects 0.000 claims description 17
- 230000009870 specific binding Effects 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 239000000945 filler Substances 0.000 claims description 14
- 238000000918 plasma mass spectrometry Methods 0.000 claims description 14
- 238000000862 absorption spectrum Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- VUEDNLCYHKSELL-UHFFFAOYSA-N arsonium Chemical compound [AsH4+] VUEDNLCYHKSELL-UHFFFAOYSA-N 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 238000010612 desalination reaction Methods 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 8
- 229920002684 Sepharose Polymers 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 239000003547 immunosorbent Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229920002401 polyacrylamide Polymers 0.000 claims description 6
- 238000012797 qualification Methods 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 238000010170 biological method Methods 0.000 claims description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 abstract description 15
- 102000001554 Hemoglobins Human genes 0.000 abstract description 15
- -1 arsenic ions Chemical class 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 abstract description 3
- 238000005406 washing Methods 0.000 description 67
- 239000007788 liquid Substances 0.000 description 57
- 229940088598 enzyme Drugs 0.000 description 54
- 239000000523 sample Substances 0.000 description 45
- 230000000694 effects Effects 0.000 description 21
- 239000013642 negative control Substances 0.000 description 19
- 239000000758 substrate Substances 0.000 description 18
- 210000003743 erythrocyte Anatomy 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 238000011534 incubation Methods 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000012160 loading buffer Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000005469 synchrotron radiation Effects 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012716 precipitator Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical group O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- 108010064719 Oxyhemoglobins Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- VDEGQTCMQUFPFH-UHFFFAOYSA-N dimethylarsinous acid Chemical compound C[As](C)O VDEGQTCMQUFPFH-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- OXBIRPQQKCQWGV-UHFFFAOYSA-N methylarsonous acid Chemical compound C[As](O)O OXBIRPQQKCQWGV-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- 208000008316 Arsenic Poisoning Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100034323 Disintegrin and metalloproteinase domain-containing protein 2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000780288 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 2 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- VHJLVAABSRFDPM-IMJSIDKUSA-N L-1,4-dithiothreitol Chemical compound SC[C@H](O)[C@@H](O)CS VHJLVAABSRFDPM-IMJSIDKUSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ZCZVZQYXVCHEKH-UHFFFAOYSA-N [O].OC(O)=O Chemical compound [O].OC(O)=O ZCZVZQYXVCHEKH-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 150000001495 arsenic compounds Chemical class 0.000 description 1
- HAYXDMNJJFVXCI-UHFFFAOYSA-N arsenic(5+) Chemical compound [As+5] HAYXDMNJJFVXCI-UHFFFAOYSA-N 0.000 description 1
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000003115 checkerboard titration Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000000673 graphite furnace atomic absorption spectrometry Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100000567 intoxicating Toxicity 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- DYFFAVRFJWYYQO-UHFFFAOYSA-N n-methyl-n-phenylaniline Chemical group C=1C=CC=CC=1N(C)C1=CC=CC=C1 DYFFAVRFJWYYQO-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- UCIYAWPLDHZJJL-UHFFFAOYSA-M sodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;hydrogen carbonate Chemical compound [Na+].OC([O-])=O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O UCIYAWPLDHZJJL-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000004876 x-ray fluorescence Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses an arsenic-hemoglobin chelate and a preparation method and application thereof, wherein the arsenic-hemoglobin chelate is prepared by chelating arsenic ions and hemoglobin through sulfydryl or/and cysteine residues. The invention establishes a qualitative and quantitative detection method of arsenic-hemoglobin chelate so as to quantitatively detect the application of arsenic-hemoglobin chelate in evaluating the arsenic pollution degree of one area. The arsenic-hemoglobin chelate in the serum of people in one region can be quantitatively detected to indirectly reflect the arsenic pollution condition of people in the region, so that the arsenic pollution degree of the region can be indirectly reflected. The accuracy of the quantitative detection method of the arsenic-hemoglobin chelate is greatly improved, and the repeatability of detection is greatly improved.
Description
Technical field
The present invention relates to detection field, more particularly, relate to a kind of arsenic-oxyphorase inner complex and its preparation method and application.
Background technology
Oxyphorase (hemoglobin; HB; HGB) be a kind of protein being responsible for delivery oxygen in higher organisms.The albumen that blood is taken on a red color.Three kinds of Hb A hemoglobin adults and Hb-A, A is had in human erythrocyte
2and F.Hb-A is the main component of oxyphorase in adult normal's red corpuscle, Hb-A
2that submember accounts for 2%, and Hb-F accounts for below 2-3% in the red corpuscle of adult normal or children, Hb-F starts embryo the main component being produced as fetal erythrocyte October, in the red corpuscle of FTNB, Hb-F accounts for 70-80%, all the other are Hb-A, account for 50% after two months, be less than 10% after four months, after six months, large portion disappears.Oxyphorase, except transports oxygen carbonic acid gas, can also cause vasospasm and vasoconstriction.The oxyphorase of the three kinds of forms existed in vivo, Oxyhemoglobins, reduced form oxyphorase and methemoglobin, wherein Oxyhemoglobins contracting vessel patency is the strongest, and methemoglobin does not almost have vasoconstriction active.
Arsenic is one of common environmental poisonous substance, is extensively present among water, soil, air and food.Due to its toxicity and universal existence, U.S.'s poisonous substance and disease registration administration (UAstedStatesAgencyforToxicSubstancesandDiseaseRegistry, ATSDR) be classified as first-class objectionable impurities (http://www.atsdr.Asc.gov/SPL/index.html) always, arsenic also (is comprised international cancer research institution (InternationalAgencyforResearchonCancer by many international organizations simultaneously, and Environmental Protection Agency (U.S.EnvironmentalProtectionAgency IARC), EPA)) delimit as one of human carcinogen.Arsenic can produce acute or chronic toxicity to human body, and acute arsenic poisoning: Report can cause the exacerbated event such as vomiting, dry, muscle spasm, stomachache, trick shouting pain, and arsenicalism has also become a significant problem of people's concern on the impact of human health.Be two kinds and contact the most direct mode by drinking water and air with arsenic in environment, it can bring out cardiovascular disorder, causes maladjusted nervous system and cause diabetes and lung cancer, skin lung cancer, bladder cancer etc.And epidemiology display at present, the underground drinking water caused at the arsenic of nature existence pollutes, in Taiwan, Argentina, Chile, West Bengal, India, Bangladesh, the Inner Mongol, multiple area such as China cause the arsenic of high dosage to expose, and becomes the global problem of environmental pollution and health risk.The current whole world has and is among the threat of arsenic exposure and arsenicalism more than 50,000,000 people.
Although the infringement of arsenic to body is fairly obvious, its mechanism causing body damage also waits research.There are positive trivalent and positive pentavalent two kinds of modal oxidation state in arsenic, a series of changes such as inorganic arsenic can be oxidized in nature and organic metabolic process, reduce, methylate, glycosylation, forms the arsenic of different shape.Inorganic arsenic is considered to the very strong form of toxicity, is listed in carcinogenic substance, wherein arsenite (iAs
iII) toxicity be better than arsenate (iAs
v); The arsenic Difference In Toxicity of different shape is very large, monomethyl arsenus acid (monomethylarsonousacid, MMA
iII) and dimethyl arsenus acid (dimethylarsinousacid, DMA
iII) all there is severe toxicity, and its pentavalent form (MMA
v, DMA
v) then toxicity is not strong.Research is thought, arsenious toxicity is by producing with protein sulfhydryl effect.Arsenic and protein binding can affect the composition of protein, structure and function, affect this protein and are combined with other functional proteins, therefore study arsenic and protein bound to understanding the toxicity of arsenic and significant to the damage mechanisms of body.
Epidemiologic data shows, the workman of Long Term Contact arsenic, and it suffers from probability of tumor in respiratory system increases greatly, and it also increases greatly because of the probability that tumor in respiratory system is lethal.The test of animal model, external model also finds, arsenic can the generation of induced tumor.Nineteen ninety, international cancer research institution (InternationalAgencyforResearchonCancer, IARC) using arsenic compound as first kind carcinogenic substance (Group1), using arsenic as 2B class carcinogenic substance (Group2B).Visible, the health of arsenic serious threat human body.
Arsenic can be combined with multiple proteins, suppresses the activity of multiple protein enzyme.Along with going deep into arsenic toxicity research, people recognize that the interaction of arsenic and albumen plays important role in its intoxicating process gradually, be considered to the key point of toxicity mechanism understanding arsenic, therefore, the research of arsenic and protein interaction just seemed ever more important.And the present mechanism about arsenic and protein effect is only tip of the iceberg, also has the relation between a lot of protein and arsenic not clear, thus strengthen for the relation between arsenic and protein most important.
Summary of the invention
For the with serious pollution problem of arsenic, the object of the present invention is to provide a kind of arsenic-oxyphorase inner complex and preparation method thereof, and set up the qualitative and quantitative analysis method of arsenic-oxyphorase inner complex, so that detection by quantitative arsenic-oxyphorase inner complex is in the application of the regional arsenic pollution level of evaluation one.Indirectly can reflect by arsenic-oxyphorase inner complex in the regional crowd's serum of detection by quantitative one situation that this regional crowd pollutes by arsenic, thus indirectly reflect this regional arsenic pollution level.
The technical solution adopted for the present invention to solve the technical problems is: provide a kind of arsenic-oxyphorase inner complex, arsonium ion and oxyphorase by sulfydryl or/and cysteine residues chelating forms.
The present invention also provides a kind of preparation method of above-mentioned arsenic-oxyphorase inner complex, comprises the following steps:
A) chelatropic reaction of arsenic and oxyphorase: add arsonium ion in the oxyphorase coming from human body or the oxyphorase of recombinating according to biological method and carry out chelatropic reaction purifying, obtain reaction soln;
B) extraction of purifying arsenic-oxyphorase inner complex: adopt immune-affinity chromatography, removes unreacted oxyphorase and unnecessary arsonium ion in reaction soln, obtains arsenic-oxyphorase inner complex.
Wherein, step B described in external synthesis method) specific as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains arsenic-oxyphorase inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of oxyphorase specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), oxyphorase and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out, obtain elutriant I;
(5) collect: collect elutriant I;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of arsenic specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out, obtain elutriant II;
(10) collect: collect elutriant II;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain arsenic-oxyphorase inner complex.
Wherein, the preparation method of above-mentioned arsenic-oxyphorase inner complex, also comprises step C): to the qualification of arsenic-oxyphorase inner complex;
Wherein, step C) in specific as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in arsenic-oxyphorase inner complex of obtaining of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out the protein band containing arsenic, this protein band is taken out and dissolves, and then adopt ELISA method or ICP-MS method or AAS method to detect the content whether containing arsenic and detection arsenic.
The present invention also provides the application of a kind of arsenic described above-oxyphorase inner complex in preparation human body in the reagent of arsenic-oxyphorase inner complex or test kit.
The present invention also provides a kind of and at least comprises the test kit of arsenic described above-oxyphorase inner complex as standard substance.
Preferably, also comprise coating buffer in this test kit, this coating buffer contains the material of catching oxyphorase or the material of catching arsenic.
The present invention also provides the method for a kind of detection by quantitative arsenic-oxyphorase inner complex, using the above-mentioned arsenic-oxyphorase inner complex of known content as standard substance, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification arsenic-oxyphorase inner complex and enzyme linked immunological combined techniques, purification arsenic-oxyphorase inner complex and atomic absorption spectrum combined techniques, purification arsenic-oxyphorase inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.
Implement arsenic of the present invention-oxyphorase inner complex and its preparation method and application, there is following beneficial effect:
1. the present invention's external synthesis arsenic-oxyphorase inner complex first;
2. the present invention proposes arsenic-oxyphorase inner complex first and can be used for preparing application in the reagent or test kit detecting arsenic-oxyphorase inner complex in blood sample.
3. the present invention establishes the method for qualitative and quantitative detection of arsenic-oxyphorase inner complex, so that detection by quantitative arsenic-oxyphorase inner complex is in the application of the regional arsenic pollution level of evaluation one.Indirectly can reflect by arsenic-oxyphorase inner complex in the regional crowd's serum of detection by quantitative one situation that this regional crowd pollutes by arsenic, thus indirectly reflect this regional arsenic pollution level.Arsenic-its accuracy of oxyphorase inner complex quantitative detecting method that the present invention sets up greatly improves, and the repeatability of detection is greatly enhanced.
Accompanying drawing explanation
Fig. 1 is the non denatured electrophoretic band figure of arsenic of the present invention-oxyphorase inner complex;
Fig. 2 is the synchrotron radiation X line fluorometric analysis figure of the electrophoretic band of arsenic of the present invention-oxyphorase inner complex.
Embodiment
Below, in conjunction with embodiment, the present invention is described further:
Unless otherwise indicated, the laboratory operating procedures related to is the step of this area routine in the present invention, and agents useful for same, material are as cited by following, and the reagent being this area conventional not enumerating out in the present invention maybe can be obtained by commercial mode:
Phosphate solution is 0.05-0.1mol/LNa
2hPO
4solution or 0.5-1mol/LNa
2hPO
4solution;
Extracting reagent is PEG solution, borate buffer solution etc. (adopting PEG method);
Glue bed medium is the one in sepharose, polyacrylamide gel;
The anti-hemoglobin antibodies of the material of catching oxyphorase to be model that Jiang Lai bio tech ltd, Shanghai produces be KAY0043; Wherein, of the present inventionly the material of catching oxyphorase is with the material of oxyphorase specific binding, anti-HB antibody, anti-hemoglobin antibodies;
The mouse-anti AsmAb of the material of catching arsenic to be model that Ran Ke bio tech ltd, Guangzhou produces be RK15728; Wherein, of the present inventionly resist with the material of arsenic specific binding, anti-As antibody, anti-arsenic antibody, arsenic the material being and catching arsenic;
Enzyme labelled antibody is the one in the antibody containing the enzyme labelling such as horseradish peroxidase, alkaline phosphatase;
Substrate is methyl diphenyl amine (TMB) solution;
The formula of erythrocyte cracked liquid is as follows: 139.6mmol/LNH
4cl, 16.96mmol/LTris, adjust pH to 7.2 with 1mol/LHCl;
Washings is for containing KH
2pO
40.2mg/ml, Na
2hPO
412H
2the pH of O2.90mg/ml, NaCl8.0mg/ml, KCl0.2mg/ml, 0.5%Tween-20 is the 0.15MPBS solution of 7.4;
Confining liquid is 1%-5% bovine serum albumin or skim-milk;
Dilution buffer is for containing 1.5mg/mLNa
2cO
3, 2.93mg/mlNaHCO
3pH be 9.6 0.05M carbonate buffer solution;
Enzyme labelled antibody is HRP enzyme labelled antibody;
Stop buffer is: by the 2MH of 21.7ml
2sO
4be settled to the ddH of 200ml
2in O;
Elutriant be containing the PH of papoid be 8.0 0.1mol/LTris-HCL damping fluid;
Souring agent is nitric acid;
Sample-loading buffer is for containing 1MTris-HCl (pH6.8) 15.5mL, 1% tetrabromophenol sulfonphthalein 2.5mL, ddH
2the Samplebuffer (5X) of O7mL, glycine 25mL;
Electrophoretic buffer be containing Tris3mg/ml, glycine 14.4mg/ml PH be the ddH of 6.8
2o solution.
The invention provides a kind of arsenic-oxyphorase inner complex, arsonium ion and oxyphorase by sulfydryl or/and cysteine residues chelating forms.
The present invention also provides the preparation method of a kind of arsenic-oxyphorase inner complex, comprises the following steps:
A) chelatropic reaction of arsenic and oxyphorase: add arsonium ion and carry out chelatropic reaction in the oxyphorase in people source, obtain reaction soln;
B) extraction of purifying arsenic-oxyphorase inner complex: adopt immune-affinity chromatography, remove unreacted oxyphorase and unnecessary arsonium ion in reaction soln, obtain arsenic-oxyphorase inner complex, concrete steps are as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains arsenic-oxyphorase inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of oxyphorase specific binding, after dress post, continue to use dilution buffer balance chromatography column; Described can be the silica gel or the resin that contain anti-hemoglobin antibodies with the filler of oxyphorase specific binding;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), oxyphorase and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out, obtain elutriant I;
(5) collect: collect elutriant I;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of arsenic specific binding, dress post after balance chromatography column by dilution buffer again; Described can be the silica gel or the resin that contain anti-arsenic antibody with the filler of arsenic specific binding;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out, obtain elutriant II;
(10) collect: collect elutriant II;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, with 2 liters of ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain arsenic-oxyphorase inner complex;
C) to the qualification of arsenic-oxyphorase inner complex, concrete steps are as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in arsenic-oxyphorase inner complex of obtaining of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out the protein band containing arsenic, this protein band is taken out and dissolves, and then adopt ELISA method or ICP-MS method or AAS method to detect the content whether containing arsenic and detection arsenic.
The present invention also provides a kind of and at least comprises the test kit of arsenic described above-oxyphorase inner complex as standard substance.
Preferably, also comprise coating buffer in this test kit, this coating buffer contains the material of catching oxyphorase or the material of catching arsenic.
In the present invention, the test kit that can realize the object of the invention can be listed following several, but is not limited to this.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise the coating buffer containing the material of catching oxyphorase, confining liquid, washings, material, enzyme labelled antibody, erythrocyte cracked liquid, substrate, stop buffer, dilution buffer, positive control, negative control etc. as two anti-caught arsenic.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise the coating buffer containing the material of catching oxyphorase, confining liquid, washings, elutriant, erythrocyte cracked liquid, positive control, negative control etc.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise the coating buffer containing the material of catching oxyphorase, confining liquid, washings, elutriant, souring agent, hydrogen peroxide, erythrocyte cracked liquid, positive control, negative control etc.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise to extract reagent needed for full blood hemoglobin as purifying, redissolve liquid, containing the coating buffer, confining liquid, washings, enzyme labelled antibody, substrate, stop buffer, dilution buffer, erythrocyte cracked liquid, positive control, negative control etc. of material of catching arsenic.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise and extract reagent, redissolution liquid, erythrocyte cracked liquid, positive control, negative control etc. needed for the full blood hemoglobin of purification.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise and extract reagent, redissolution liquid, souring agent, hydrogen peroxide, erythrocyte cracked liquid, positive control, negative control etc. needed for the full blood hemoglobin of purification.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise as the extraction reagent of full blood hemoglobin of purifying, glue bed medium, to redissolve on liquid, sample-loading buffer, dissolving glue bed containing liquid needed for the protein band of arsenic, containing the coating buffer, confining liquid, washings, enzyme labelled antibody, substrate, stop buffer, dilution buffer, positive control, negative control etc. of material of catching arsenic.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise and to extract reagent, glue bed medium as purifying needed for full blood hemoglobin, redissolving on liquid, sample-loading buffer, dissolving glue bed containing liquid, positive control, negative control etc. needed for the protein band of arsenic.
Detect a test kit for arsenic in blood sample-oxyphorase inner complex, comprise and to extract reagent, glue bed medium as purifying needed for full blood hemoglobin, redissolving on liquid, sample-loading buffer, dissolving glue bed containing liquid, souring agent, hydrogen peroxide, erythrocyte cracked liquid, positive control, negative control etc. needed for the protein band of arsenic.
In above-mentioned several test kit, described positive control is standard substance, is namely chelated with the oxyphorase inner complex of heavy arsenic or is chelated with the BSA inner complex of heavy arsenic; Described negative control is the dilution buffer not containing standard substance.
Mentioned reagent box is for detecting the oxyphorase of chelating arsenic, to improve the accuracy of detection, repeated, and makes it to be promoted in clinical.
The present invention also provides the method for a kind of detection by quantitative arsenic-oxyphorase inner complex, using the above-mentioned arsenic-oxyphorase inner complex of known content as standard substance, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification arsenic-oxyphorase inner complex and enzyme linked immunological combined techniques, purification arsenic-oxyphorase inner complex and atomic absorption spectrum combined techniques, purification arsenic-oxyphorase inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.In the present invention, following several with having of detecting that the method for arsenic-oxyphorase inner complex can list, but be not limited to following several.
Wherein, the reagent adopted in the method for above-mentioned detection by quantitative arsenic-oxyphorase inner complex is as follows:
method one:euzymelinked immunosorbent assay (ELISA) (ELISA method) detects arsenic-oxyphorase inner complex, detects in accordance with the following steps:
1) material of oxyphorase can be caught, as anti-hemoglobin antibodies (anti-HBAb) is coated on solid phase carrier: by dilution buffer, anti-HBAb is diluted to 500-4000 doubly, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, add deionized water by whole blood, then add erythrocyte cracked liquid, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the arsenic of known content-oxyphorase inner complex; By dilution buffer, measuring samples is diluted to 10-40 doubly, adds in micropore, 37 DEG C of effect 1-2 hour;
5) material can catching arsenic is added, and incubation: remove measuring samples, and wash with washings, after washing completes, add and be diluted to 25000-200000 anti-AsAb doubly by dilution buffer, 37 DEG C of effect 1-2 hour, make the arsenic on anti-AsAb and oxyphorase react and form immune complex;
6) enzyme conjugates incubation: remove anti-arsenic antibody, and wash with washings, after washing completes, add the enzyme labelled antibody with dilution buffer dilution, make the concentration of the enzyme labelled antibody of dilution be 2 μ g/mL, 37 DEG C of effect 1-2 hour, make itself and enzyme labelled antibody react;
7) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
8) termination reaction: stop buffer is dropped to each micropore;
9) wavelength 405nm is got, after adding stop buffer, elisa plate is placed in microplate reader and detects, read the OD value of measuring samples and standard substance respectively, by drawing standard curve, try to achieve the content (also microplate reader can not be used, directly carry out qualitative detection by colour developing situation) of measuring samples.
The method utilizes ELISA principle, specificity oxyphorase in whole blood can be extracted, the oxyphorase upper part extracted is chelated with heavy arsenic, and the arsenic on this part oxyphorase catch by anti-arsenic antibody, afterwards can again by horseradish peroxidase, the antibody of the enzyme labellings such as alkaline phosphatase is caught (this antibody nonrecognition coating protein), the antibody of catching is under the effect of developer and stop buffer, OD value can be read under instrument, and the oxyphorase not containing chelating arsenic, then can not catch by the specific antibody of anti-arsenic, also can not with horseradish peroxidase, the antibody of the enzyme labellings such as alkaline phosphatase caught, and also not containing arsenic (negative control group result is negative) in agents useful for same, thus when read OD value result is shown as the positive, the i.e. provable arsenic detecting chelating on oxyphorase.
method two:enzyme linked immunological and atomic absorption spectrum combined techniques (ELISA method+AAS method) detect arsenic-oxyphorase inner complex and detect in accordance with the following steps:
1) material of oxyphorase can be caught, as anti-hemoglobin antibodies (anti-HBAb) is coated on solid phase carrier: by dilution buffer, anti-HBAb is diluted to 500-4000 doubly, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, add deionized water by whole blood, then add erythrocyte cracked liquid, the centrifugal 5-8 minute of 1000rpm, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the arsenic of known content-oxyphorase inner complex; By dilution buffer, measuring samples is diluted to 10-40 doubly, adds in micropore, 37 DEG C of effect 1-2 hour;
5) wash-out: remove measuring samples, and wash with washings, after washing completes, add elutriant, wash-out 1-3 hour glue bed at 37 DEG C.
6) detect: sample from the micropore of elisa plate, detect the arsenic of chelating on oxyphorase in Atomic Absorption Spectroscopy AAS, and drawing standard curve, readout value;
In conjunction with atomic absorption spectrum (AAS) principle on the basis that the method utilizes ELISA principle, Atomic Absorption Spectroscopy AAS is utilized to detect the arsenic of chelating on oxyphorase, owing to only containing oxyphorase in solution, and not containing any arsenic (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, i.e. the provable arsenic detecting chelating on oxyphorase.
method three:enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques (ELISA method+ICP-MS method) detect arsenic-oxyphorase inner complex and detect in accordance with the following steps:
1) material of oxyphorase can be caught, as anti-hemoglobin antibodies (anti-HBAb) is coated on solid phase carrier: by dilution buffer, anti-HBAb is diluted to 500-4000 doubly, add in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, add deionized water by whole blood, then add erythrocyte cracked liquid, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the arsenic of known content-oxyphorase inner complex; By dilution buffer, measuring samples is diluted to 10-40 doubly, adds in micropore, 37 DEG C of effect 1-2 hour;
5) wash-out: remove measuring samples, and wash with washings, after washing completes, add elutriant, wash-out 1-3 hour glue bed at 37 DEG C.
6) acidifying: in step 5) in solution in add souring agent acidifying carried out to solution, sealing is spent the night, and thorough acidifying, adds hydrogen peroxide, and acid is caught up with in heating;
7) detect: from step 6) elisa plate solution get 0.5ml liquid, under icp ms, detect chelating in the arsenic of oxyphorase, and drawing standard curve, readout value.
The method is on the basis utilizing ELISA principle, in conjunction with sense coupled plasma mass spectrometry (ICP-MS) principle, the arsenic of chelating on oxyphorase is detected with icp ms, owing to only containing oxyphorase in solution, and not containing any arsenic (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, i.e. the provable arsenic detecting chelating on oxyphorase.
method four:purification arsenic-oxyphorase inner complex and enzyme linked immunological combined techniques (method of purification+ELISA method) detect arsenic-oxyphorase inner complex, detect in accordance with the following steps:
1) from whole blood, oxyphorase is extracted: adopt the polyoxyethylene glycol PEG precipitator method or ultracentrifugation or the method such as molecule ultrafiltration or gel-filtration from the oxyphorase whole blood extraction purification blood, and redissolve in solution by oxyphorase, obtain hemoglobin solutions;
2) anti-AsAb is coated on solid phase carrier: by dilution buffer, anti-AsAb is diluted to 25000-200000 doubly, adds in elisa plate micropore, 4 DEG C of 16-18 hour that spend the night, or 37 DEG C of water-bath 1-3 hour, store refrigerator;
3) close: remove dilution buffer, and wash with washings, after washing completes, add using 1%-5% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C, after having washed, elisa plate places 1-2 hour in 36.5-37.5 DEG C;
4) add measuring samples, and incubation: from step 1) solution sample, make measuring samples; Standard substance are made with the arsenic of known content-oxyphorase inner complex; By dilution buffer, measuring samples is diluted to 10-40 doubly, adds in micropore, 37 DEG C of effect 1-2 hour;
5) enzyme conjugates incubation: remove step 4) in measuring samples, and to wash with washings, after washing completes, add the enzyme labelled antibody with dilution buffer dilution, make the concentration of the enzyme labelled antibody of dilution be 2 μ g/mL, 37 DEG C of effect 1-2 hour, make itself and enzyme labelled antibody react;
6) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
7) termination reaction: stop buffer is dropped to each micropore;
8) wavelength 405nm is got, after adding stop buffer, elisa plate is placed in microplate reader and detects, read the OD value of measuring samples and standard substance respectively, by drawing standard curve, try to achieve the content (also microplate reader can not be used, directly carry out qualitative detection by colour developing situation) of measuring samples.
method five:purification arsenic-oxyphorase inner complex and atomic absorption spectrum combined techniques (method of purification+AAS method) detect arsenic in blood sample-oxyphorase inner complex, detect in accordance with the following steps:
1) from whole blood, oxyphorase is extracted: adopt the polyoxyethylene glycol PEG precipitator method or ultracentrifugation or the method such as molecule ultrafiltration or gel-filtration from the oxyphorase whole blood extraction purification blood, and redissolve in solution by oxyphorase, obtain hemoglobin solutions;
2) detect: from step 1) sample the solution that obtains, detect the arsenic of chelating on oxyphorase in Atomic Absorption Spectroscopy AAS, and drawing standard curve, readout value.
method six:purification arsenic-oxyphorase inner complex and inductivity coupled plasma mass spectrometry combined techniques (method of purification+ICP-MS method) detect arsenic-oxyphorase inner complex, detect in accordance with the following steps:
1) from whole blood, oxyphorase is extracted: adopt the polyoxyethylene glycol PEG precipitator method or ultracentrifugation or the method such as molecule ultrafiltration or gel-filtration from the oxyphorase whole blood extraction purification blood, and redissolve in solution by oxyphorase, obtain hemoglobin solutions;
2) acidifying: from step 1) sample the solution that obtains, add souring agent (as nitric acid) in the solution and carry out acidifying to solution, sealing is spent the night, and thorough acidifying, adds hydrogen peroxide, and acid is caught up with in heating;
3) detect: from step 2) get 0.5ml liquid the solution that obtains, under icp ms, detect the arsenic of chelating on oxyphorase, and drawing standard curve, readout value.
method seven:electrophoresis and euzymelinked immunosorbent assay (ELISA) or atomic absorption spectrometry or inductivity coupled plasma mass spectrometry combined techniques (electrophoretic method-ELISA method/AAS method/ICP-MS method) detect arsenic-oxyphorase inner complex, detect in accordance with the following steps:
1) from whole blood, oxyphorase is extracted: adopt the polyoxyethylene glycol PEG precipitator method or ultracentrifugation or the method such as molecule ultrafiltration or gel-filtration from the oxyphorase whole blood extraction purification blood, and redissolve in solution by oxyphorase, obtain hemoglobin solutions;
2) glue bed is prepared: select sepharose or polyacrylamide gel or SDS-polyacrylamide gel etc. as medium as required, conventionally prepare glue bed;
3) application of sample: get step 1) the solution 8 μ L that obtains adds 2 μ L sample-loading buffers, mixing, of short duration centrifugal; (noticing that step can not be boiled herein)
4) electrophoresis: connect electrophoresis plate, carry out electrophoretic separation;
5) detect: on glue bed, find out the protein band containing arsenic, this band is taken out, this protein band is dissolved among liquid, and then utilize ELISA or ICP-MS or AAS to detect the arsenic content be dissolved in liquid respectively.In addition, the iso-electric point of the oxyphorase of this method detection chelating arsenic, molecular weight and content etc. can also be utilized.
After oxyphorase in method seven discharges from red corpuscle can with multiple Methods For Purification out (such as ultracentrifugation or HPLC or gel-filtration chromatography or gel electrophoresis or ELISA method etc.), the oxyphorase of purifying out is redissolved in solution, get a certain amount of oxyphorase, utilize electric charge shifting principle, carry out electrophoresis (electrophoresis, EP), can according to molecular weight on gel slab (different media can be adopted as required), the difference such as iso-electric point runs out of different bands, find out the respective strap being rich in arsenic, protein in gel is redissolved in solution, namely the content of relevant oxyphorase can be detected at a particular wavelength, also the principle such as ELISA or AAS or ICP-MS can be utilized to detect the arsenic content of chelating on oxyphorase, owing to only containing oxyphorase in solution, and not containing any arsenic (negative control group result is negative) in agents useful for same, interference can not be caused to result, thus when read result is shown as the positive, the i.e. provable arsenic detecting chelating on oxyphorase.
Below in conjunction with embodiment, the present invention is further described.
embodiment 1: the preparation method of arsenic-oxyphorase inner complex, comprises the following steps:
A) chelatropic reaction of arsenic and oxyphorase: add arsonium ion and carry out chelatropic reaction in the oxyphorase in people source, obtain reaction soln;
Preparation of reagents:
1) borate buffer solution (0.01M): take 0.31g boric acid and be dissolved in 400ml ultrapure water, regulates pH to 9.0 with the NaOH of 0.1M, is settled to 500mL.
2) hemoglobin solutions: take 4.0mg oxyphorase and be dissolved in 4.0mL0.01MpH9.0 borate buffer solution, dissolving of fully vibrating, is mixed with the protein solution of 1.0mg/mL;
3) EDTA-NaHCO3 mixing solutions: take EDTA2H
2o1.86g, NaHCO
316.8g is dissolved in 900mL ultrapure water, adjusts pH to 8.0 be settled to 1000ml, autoclaving, room temperature preservation with 1.0MNaOH;
4) ITCBE buys from Japanese colleague's chemistry institute, and article No. is M030;
5) dialysis tubing is purchased from BioshopInc, molecular weight cut-off 14000.
The chelation step of arsenic-oxyphorase inner complex:
1) process of dialysis tubing: EDTA-NaHCO dialysis tubing being put into 500ml
3in mixing solutions, boil 10min; Tipping EDTA/NaHCO
3liquid, with ultrapure water rinsing gently, then boils 10min with the 5mmol/LEDTA solution of 500ml; Discard boiling liquid, thoroughly clean with ultrapure water, add ultrapure water immersion dialysis tubing 4 DEG C and spend the night.During use, put on one's gloves, take out dialysis tubing, with its surfaces externally and internally of ultrapure water cleaning down;
2) getting 2.0mgITCBE is dissolved in 2mlDMSO;
3) getting 4.0mg oxyphorase is dissolved in 4.0ml borate buffer solution;
4) slowly by step 2) liquid prepared adds step 3) in the hemoglobin solutions prepared, dropping limit, limit is shaken, and being placed in temperature is 25 DEG C, and rotating speed is react 24h in the shaking table of 100r/min, then to dialyse 24h with dialysis tubing, remove the ITCBE be not combined with oxyphorase;
5) by step 4) the liquid 1mol/LHCl adjust ph to 7.0 of gained, then slowly drip the 1mmol/L arsenic ion soln of 80 μ l gradually, dropping limit, limit vibrates, in order to avoid arsonium ion makes protein denaturation precipitate;
6) by step 5) to be placed in temperature be 25 DEG C for the solution of gained, rotating speed is react 2h in the shaking table of 100r/min, carries out dialysis 24h with dialysis tubing;
7) by step 6) dialysis after liquid preserve in-20 DEG C of packing, obtain reaction soln.
B) extraction of purifying arsenic-oxyphorase inner complex: adopt immune-affinity chromatography, remove reaction soln (the i.e. step 7) reaction soln that obtains) in unreacted oxyphorase and unnecessary arsonium ion, obtain arsenic-oxyphorase inner complex, concrete steps are as follows:
(1) sample dissolution: to through step 7) add physiological saline in the reaction soln that obtains arsenic-oxyphorase inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of oxyphorase specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), oxyphorase and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out, obtain elutriant I;
(5) collect: collect elutriant I;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of arsenic specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out, obtain elutriant II;
(10) collect: collect elutriant II;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, with 2 liters of ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain arsenic-oxyphorase inner complex;
C) to the qualification of arsenic-oxyphorase inner complex, concrete steps are as follows:
(1) glue bed is prepared: prepare glue bed using sepharose as medium;
(2) application of sample: get step B) in arsenic-oxyphorase inner complex of obtaining of 8 μ L extraction purification, add 2 μ L sample-loading buffers, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, add electrophoretic buffer and carry out electrophoresis; In electrophoresis process, electric current is 22mA constant current, and envrionment temperature is 4 DEG C; Electrophoresis stops electrophoresis to when moving to bottom glue to tetrabromophenol sulfonphthalein;
(4) detect: on glue bed, find out the protein band containing arsenic, this protein band is taken out and dissolves, and then adopt ELISA method or ICP-MS method or AAS method to detect the content whether containing arsenic and detection arsenic.
D) detected result
(1) arsenic content in graphite furnace atomic absorption spectrometry (AAS) rough determination HB: the results are shown in Table 1
Table 1 is arsenic content in oxyphorase (μ g/L)
Sample name | As(μg/L) |
HB | 263.28 |
(NH 4) 2SO 4 | 0.07 |
N.S | 0 |
N.S | 0.014 |
(2) electrophoresis result:
Wherein, Fig. 1 is the non denatured electrophoretic band figure of arsenic of the present invention-oxyphorase inner complex.
Native polyacrylamide gel electrophoresis (Native-PAGE) or be called that active electrophoresis is under the condition not adding the denaturing agent such as SDS and thin base ethanol, to keeping active protein to carry out polyacrylamide gel electrophoresis, be usually used in the qualification of enzyme, Isozyme Analysis and purification.The native polyacrylamide gel electrophoresis not adding SDS can make biomacromolecule in electrophoresis process, keep its natural shape and electric charge, their separation is the molecular sieve effect of difference according to its electrophoretic mobility and gel, thus higher resolving power can be obtained, especially after electrophoretic separation, still can keep the biological activity of the biomacromolecule such as protein and enzyme, therefore left lane M is sex change Marker, only for detecting, do not mark effect, swimming lane Hb is hemoglobin electrophoresis band.
(3) Synchrotron Radiation X-Ray Fluorescence Anal ysis:
In protein band, the SRXRF of micronutrient levels analyzes and " synchrotron radiation bunch completes at the 4W1 of Beijing electron positron collider (BEPC).In storage ring, beam current energy is 2.2GeV, beam intensity 100mA.Sample transfer table (TSA200 type, Beijing stand upright Han Guang company) can move up to change launching spot position along X, Y two-dimensional square under computer-controlled step motor drives, and moving step length is 0.0025mm.The X-ray gone out from electromagnetic radiation is detected by Si (Li) detector (PGTInc.LS30143-DS), probe is mutually vertical with incident SR line copline, apart from sample irradiation point 20mm, signal obtains with PGT MCA (MCA4000) and exports.By the monochromatic synchrotron radiation light excited sample of 11.5keV, launching spot (1mmx3mm) position is regulated to make it to be in band one end, in the minute of 300s, hot spot is always along band evenly slowly movement, and at the end of counting, hot spot moves on to this band the other end.A spectrum is got along the every 1mm in electrophoresis direction.Adopt AXIL software data processing, and with deriving from air and the Ar fignal center of content constant carries out normalization to other element peak, to offset the impact that beam intensity change produces signal power.Measure the fluorescence Spectra of the dry glued membrane of quantitative criterion at identical conditions in the same way.
Fig. 2 is the synchrotron radiation X line fluorometric analysis figure of the electrophoretic band of arsenic of the present invention-oxyphorase inner complex, and in figure, X-coordinate is protein band position, and ordinate zou is energy (content) value of each arsenic of this band.
the determination of the testing conditions of the method for a kind of detection by quantitative arsenic-oxyphorase inner complex of the present invention:
1. the determination of the optimum diluting multiple of anti-hemoglobin antibodies, anti-arsenic antibody best effort concentration and whole blood
Step is as follows:
(1) be that 1:500,1:1000,1:2000,1:4000 dilute by anti-HBAb dilution buffer according to the mass volume ratio of anti-HBAb and dilution buffer, add in elisa plate micropore, be coated on solid phase carrier by anti-HBAb, each concentration bag is by three rows, and 4 DEG C are spent the night 18 hours;
(2) remove dilution buffer, and wash with washings, after washing completes, with 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C;
(3) measuring samples is that 1:10,1:20,1:40 dilute by the mass volume ratio of measuring samples and dilution buffer, add in micropore, according to the anti-HBAb concentration of above-mentioned bag quilt, the anti-HBAb of same concentration adds different extent of dilution whole blood respectively, 37 DEG C of effects 1 hour;
(4) measuring samples is removed, and wash with washings, after washing completes, add anti-AsAb, anti-AsAb is that 1:25000,1:50000,1:100000,1:200000 dilute by the mass volume ratio of anti-AsAb and dilution buffer, and according to each identical anti-HBAb, serum-dilution concentration, the anti-AsAb of different concns respectively adds 2 holes, 37 DEG C act on 1 hour, the arsenic on anti-AsAb and HB are reacted;
(5) enzyme labelled antibody selects the suitableeest working concentration, and 2 μ g/mL, remove anti-As antibody, and wash with washings, after washing completes, add with dilution buffer dilution HRP enzyme labelled antibody, 37 DEG C act on 1 hour, HRP enzyme labelled antibody and arsenic-oxyphorase inner complex are reacted;
(6) remove enzyme labelled antibody, and wash with washings, after washing completes, add substrate, 37 DEG C of lucifuge effects 30 minutes;
(7) stop buffer is dropped to each micropore;
(8) get wavelength 405nm, after adding stop buffer, elisa plate is placed in microplate reader and detects, read each hole OD value respectively.According to each hole OD value numerical value, select the best effort concentration of anti-HBAb, anti-AsAb and the optimum diluting multiple of whole blood.
Simultaneously using made standard substance as positive control in test, select anti-HBAb+ close+anti-AsAb+ enzyme mark+substrate (namely not adding measuring samples) is as negative control 1; Anti-HBAb+ closes+and whole blood+enzyme mark+substrate (namely not adding anti-AsAb) is as negative control 2; Anti-HBAb+ closes+and enzyme mark+substrate (namely not adding measuring samples and anti-AsAb) is as negative control 3; Anti-HBAb+ closes+and whole blood+anti-AsAb+ substrate (i.e. not enzyme-added mark) is as negative control 4; Closed+whole blood+anti-AsAb+ enzyme mark+substrate (namely do not add anti-HBAb and catch HB) is as blank 1; Only add substrate as blank 2 and PBS as blank 3.Detected result is in Table 2-3.
Table 2: Checkerboard titration method determines the data (each data are all mean value) of the best effort concentration of anti-HBAb, anti-AsAb and the optimum diluting multiple of whole blood
Table 3:ELISA positive control and negative control ELISA detected result
By table 2-3 data presentation, when we can find out, and the extent of dilution as anti-HBAb is 1:1000, whole blood extent of dilution be the anti-extent of dilution of 1:20, As is 1:25000, OD value is maximum, so select concentration corresponding to this value as best effort concentration.
2. the determination of elutriant best effort concentration and elution time in method two, three in the method for detection by quantitative arsenic-oxyphorase inner complex
Step is as follows: (1) bag quilt: anti-As antibody dilution buffer be diluted to 25000 times (mass volume ratios), add in elisa plate micropore, 37 DEG C of water-baths 3 hours, stores refrigerator;
(2) remove dilution buffer, and wash with washings, after washing completes, with 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid, and wash with washings for 37 DEG C;
(3) remove confining liquid, and wash with washings, after washing completes, add the enzyme labelled antibody with dilution buffer dilution, it is 2 μ g/mL that enzyme labelled antibody is diluted to concentration, and 37 DEG C act on 2 hours, itself and anti-AsAb are reacted;
(4) prepare elutriant: papoid pH8.0,0.1mol/LTris-HCI buffer is become 100ng/ml, then add 1mmol/L dithiothreitol (DTT) (DTT) 37 DEG C and hatch 30min;
(5) enzyme labelled antibody is removed,
By dilution buffer, elutriant is diluted, make the concentration of the papoid in elutriant and the ratio of the concentration of enzyme labelled antibody be 1:80,1:40,1:20,1:10,1:5 (wherein each concentration does 3 multiple holes), be positioned over wash-out 1h, 2h, 3h at 37 DEG C of temperature respectively;
(6) remove elutriant, and wash with washings, after washing completes, add substrate, 37 DEG C of lucifuge effects 30 minutes;
(7) stop buffer is dropped to each micropore;
(8) get 405nm wavelength, after adding stop buffer, be placed in by elisa plate in microplate reader and detect, read respectively and often organize OD value, by comparing with PBS damping fluid group, compare optimal concentration and the elution time of elutriant, concrete outcome is see table 4.
Table 4:ELISA elutriant best effort concentration and elution time are determined
From table 4, we can find, as the ratio=1:20 of the concentration of the papoid in elutriant with the concentration of enzyme labelled antibody, each group of OD value is all lower than other several groups, this concentration elution effect optimum (reach maximum by the anti-AsAb-enzyme mark mixture wash-out degree that ELISA hole wall combines, thus OD value is minimum) is described; And no matter elution time is 1h, 2h, 3h, the change of each group OD value is all little, as seen along with the prolongation of time, enzyme activity weakens gradually, when enzyme concn is constant, extends digestion time and can not improve digestibility, so the elution time of elutriant is that 1-3h all can in this test.
application Example 1
Get and adopt ELISA method to detect arsenic-oxyphorase inner complex in 100 parts of sample whole bloods, detect according to following steps: euzymelinked immunosorbent assay (ELISA) (ELISA method) detects arsenic-oxyphorase inner complex, detect in accordance with the following steps:
1) anti-HBAb is coated on solid phase carrier: by dilution buffer, anti-HBAb is diluted to 1000 times, adds in elisa plate micropore, 37 DEG C of water-baths 1 hour, store refrigerator;
2) get whole blood from the recycle system, make measuring samples, add deionized water by whole blood, then add erythrocyte cracked liquid, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the arsenic of known content-oxyphorase inner complex; By dilution buffer, measuring samples is diluted to 20 times, adds in micropore, 37 DEG C act on 1 hour;
5) material can catching arsenic is added, and incubation: remove measuring samples, and wash with washings, after washing completes, add and dilute 25000 times by dilution buffer, 37 DEG C act on 1 hour, the arsenic on anti-AsAb and oxyphorase are reacted;
6) enzyme conjugates incubation: remove anti-arsenic antibody, and wash with washings, after washing completes, adds the HRP enzyme labelled antibody with dilution buffer dilution, and 37 DEG C act on 1 hour, itself and enzyme labelled antibody are reacted;
7) substrate incubation: remove enzyme labelled antibody, and wash with washings, after washing completes, adds substrate, 37 DEG C of lucifuge effects 30 minutes;
8) termination reaction: stop buffer is dropped to each micropore;
9) getting wavelength is 405nm, after adding stop buffer, is placed in by elisa plate in microplate reader and detects, and read measuring samples OD value (also can not use microplate reader, directly carry out qualitative detection by colour developing situation) respectively, concrete detected value is as shown in table 5.
The ELISA detected result of arsenic-oxyphorase inner complex in table 5:100 part blood sample
application Example 2
Employing enzyme linked immunological and atomic absorption spectrum combined techniques (ELISA method+AAS method) detect the arsenic-oxyphorase inner complex in 100 points of sample blood samples, detect in accordance with the following steps:
1) can catch the material of oxyphorase, as anti-hemoglobin antibodies (anti-HBAb) is coated on solid phase carrier: by dilution buffer, anti-HBAb is diluted to 1000 times, adds in elisa plate micropore, 4 DEG C are spent the night 18 hours;
2) get whole blood from the recycle system, make measuring samples, add deionized water by whole blood, then add erythrocyte cracked liquid, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin or skim-milk as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the arsenic of known content-oxyphorase inner complex; By dilution buffer, measuring samples is diluted to 20 times, adds in micropore, 37 DEG C act on 1 hour;
5) wash-out: remove measuring samples, and wash with washings, after washing completes, add the elutriant that Papain enzyme concn is 100ng/ml, wash-out 1-3 hour;
6) detect: sample from the micropore of elisa plate, detect the arsenic of chelating on oxyphorase in Atomic Absorption Spectroscopy AAS, detected value is as shown in table 6.
The AAS detected result of arsenic-oxyphorase inner complex in table 6:100 part blood sample
application Example 3
Employing enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques (ELISA method+ICP-MS method) detect the arsenic-oxyphorase chelate content in 100 points of sample blood samples, detect in accordance with the following steps:
1) can catch the material of oxyphorase, as anti-hemoglobin antibodies (anti-HBAb) is coated on solid phase carrier: by dilution buffer, anti-HBAb is diluted to 1000 times, adds in elisa plate micropore, 4 DEG C are spent the night 18 hours;
2) get 100 parts of standard blood samples as measuring samples, add deionized water by whole blood, then add erythrocyte cracked liquid, the centrifugal 5-8 minute of 1000rmp, centrifugally discard precipitation;
3) close: remove dilution buffer, and wash with washings, after washing completes, add 2% bovine serum albumin as confining liquid, place 1 hour, remove confining liquid for 37 DEG C, and wash with washings, after having washed, elisa plate is placed 1 hour in 37 DEG C;
4) add measuring samples, and incubation: add step 2) in measuring samples, make standard substance with the arsenic of known content-oxyphorase inner complex; By dilution buffer, measuring samples is diluted to 20 times, adds in micropore, 37 DEG C act on 1 hour;
5) wash-out: remove measuring samples, and wash with washings, after washing completes, add the elutriant that Papain enzyme concn is 100ng/ml, wash-out 1-3 hour;
6) acidifying: in step 5) in solution in add nitric acid acidifying carried out to solution, sealing is spent the night, and thorough acidifying, adds hydrogen peroxide, and acid is caught up with in heating;
7) detect: from step 6) sample the solution that obtains, under icp ms, detect chelating in the arsenic of oxyphorase, detected value is as shown in table 7.
The ICP-MS detected result of arsenic-oxyphorase inner complex in table 7:100 part blood sample
To one skilled in the art, according to technical scheme described above and design, other various corresponding change and deformation can be made, and all these change and deformation all should belong within the protection domain of the claims in the present invention.
Claims (8)
1. arsenic-oxyphorase inner complex, is characterized in that, arsonium ion and oxyphorase by sulfydryl or/and cysteine residues chelating forms.
2. a preparation method for arsenic as claimed in claim 1-oxyphorase inner complex, is characterized in that, comprise the following steps:
A) chelatropic reaction of arsenic and oxyphorase: add arsonium ion in the oxyphorase coming from human body or the oxyphorase of recombinating according to biological method and carry out chelatropic reaction purifying, obtain reaction soln;
B) extraction of purifying arsenic-oxyphorase inner complex: adopt immune-affinity chromatography, removes unreacted oxyphorase and unnecessary arsonium ion in reaction soln, obtains arsenic-oxyphorase inner complex.
3. preparation method according to claim 2, is characterized in that,
Described step B) specific as follows:
(1) sample dissolution: to through steps A) add physiological saline in the reaction soln that obtains arsenic-oxyphorase inner complex is redissolved;
(2) balance chromatography column: use dilution buffer to rinse the pipeline of chromatography column, load in chromatography column can with the filler of oxyphorase specific binding, after dress post, continue to use dilution buffer balance chromatography column;
(3) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (1), oxyphorase and filler specific binding;
(4) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.05-0.1mol/L to carry out wash-out, obtain elutriant I;
(5) collect: collect elutriant I;
(6) dialyse: by the elutriant of the collection in step (5), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample;
(7) balance chromatography column: adopt new chromatography column, use dilution buffer flushing pipeline, in this chromatography column load can with the filler of arsenic specific binding, dress post after balance chromatography column by dilution buffer again;
(8) loading: after chromatography column balance, with sample, then upper prop in dilution buffer dilution step (6);
(9) wash-out: use dilution buffer to rinse chromatography column and balance to baseline, then use the phosphate solution of 0.5-1.0mol/L to carry out wash-out, obtain elutriant II;
(10) collect: collect elutriant II;
(11) dialyse: by the elutriant of the collection in step (10), dress dialysis tubing, uses ddH
2o dialyses desalination, and after changing water three times, 4 DEG C of dialysed overnight, collect sample, obtain arsenic-oxyphorase inner complex.
4. the preparation method of arsenic according to claim 2-oxyphorase inner complex, is characterized in that, also comprise step C): to the qualification of arsenic-oxyphorase inner complex;
Wherein, step C) in specific as follows:
(1) glue bed is prepared: prepare glue bed using the one in sepharose, polyacrylamide gel as medium;
(2) application of sample: get step B) in arsenic-oxyphorase inner complex of obtaining of extraction purification, add dilution buffer, and mix, then application of sample is in sample cell;
(3) electrophoresis: connect electrophoresis plate, carry out electrophoresis;
(4) detect: on glue bed, find out the protein band containing arsenic, this protein band is taken out and dissolves, and then adopt ELISA method or ICP-MS method or AAS method to detect the content whether containing arsenic and detection arsenic.
5. the application of arsenic as claimed in claim 1-oxyphorase inner complex in the reagent or test kit preparing to detect arsenic-oxyphorase inner complex in blood sample.
6. one kind at least comprises the test kit of arsenic as claimed in claim 1-oxyphorase inner complex as standard substance.
7. test kit according to claim 6, is characterized in that, also comprises coating buffer, and this coating buffer contains the material of catching oxyphorase or the material of catching arsenic.
8. the method for detection by quantitative arsenic-oxyphorase inner complex, it is characterized in that, using the arsenic according to claim 1-oxyphorase inner complex of known content as standard substance, a pair sample of following methods is adopted to detect: euzymelinked immunosorbent assay (ELISA), enzyme linked immunological and atomic absorption spectrum combined techniques, enzyme linked immunological and inductivity coupled plasma mass spectrometry combined techniques, purification arsenic-oxyphorase inner complex and enzyme linked immunological combined techniques, purification arsenic-oxyphorase inner complex and atomic absorption spectrum combined techniques, purification arsenic-oxyphorase inner complex and inductivity coupled plasma mass spectrometry combined techniques, electrophoresis and enzyme linked immunological or atomic absorption spectrum or inductivity coupled plasma mass spectrometry combined techniques.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510413076.1A CN105037533A (en) | 2015-07-14 | 2015-07-14 | Arsenic-hemoglobin chelate as well as preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510413076.1A CN105037533A (en) | 2015-07-14 | 2015-07-14 | Arsenic-hemoglobin chelate as well as preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105037533A true CN105037533A (en) | 2015-11-11 |
Family
ID=54444544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510413076.1A Pending CN105037533A (en) | 2015-07-14 | 2015-07-14 | Arsenic-hemoglobin chelate as well as preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105037533A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006123343A2 (en) * | 2005-05-18 | 2006-11-23 | Ramot At Tel Aviv University Ltd. | Biologically active metal-coated proteins |
-
2015
- 2015-07-14 CN CN201510413076.1A patent/CN105037533A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006123343A2 (en) * | 2005-05-18 | 2006-11-23 | Ramot At Tel Aviv University Ltd. | Biologically active metal-coated proteins |
Non-Patent Citations (2)
Title |
---|
刘冬等: "免疫亲和层析", 《生物分离技术》 * |
吴士良等: "脂蛋白琼脂糖凝胶电泳鉴定", 《生物化学与分子生物学实验教程》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105037533A (en) | Arsenic-hemoglobin chelate as well as preparation method and application thereof | |
CN104987400A (en) | Mercury-hemoglobin chelate as well as preparation method and application thereof | |
CN104987412A (en) | Arsenic-IgE chelate as well as preparation method and application thereof | |
CN105021548B (en) | Arsenic-fibrinogen chelate as well as preparation method and application thereof | |
CN104987389A (en) | Arsenic-albumin chelate as well as preparation method and application thereof | |
CN105001321A (en) | Mercury-fibrinogen chelate and preparation method and application thereof | |
CN104987409A (en) | Lead-IgG chelate as well as preparation method and application thereof | |
CN105004684A (en) | Nickel-IgE chelate as well as preparation method and application thereof | |
CN104987402A (en) | Lead-hemoglobin chelate as well as preparation method and application thereof | |
CN105044006B (en) | Mercury-IgG chelate and preparation method and application thereof | |
CN105044004B (en) | Mercury-IgM chelate as well as preparation method and application thereof | |
CN104987401A (en) | Cadmium-hemoglobin chelate as well as preparation method and application thereof | |
CN104987411A (en) | Cadmium-IgA chelate as well as preparation method and application thereof | |
CN104987405B (en) | A kind of arsenic IgG chelates and its preparation method and application | |
CN104987403A (en) | Nickel-hemoglobin chelate as well as preparation method and application thereof | |
CN105001324A (en) | Chromium-hemoglobin chelate as well as preparation method and application thereof | |
CN104987414A (en) | Nickel-IgM chelate as well as preparation method and application thereof | |
CN104987390A (en) | Cadmium-albumin chelate as well as preparation method and application thereof | |
CN104987415A (en) | Chromium-IgM chelate as well as preparation method and application thereof | |
CN104987408A (en) | Mercury-IgA chelate as well as preparation method and application thereof | |
CN104987404A (en) | Nickel-IgG chelate as well as preparation method and application thereof | |
CN105021554A (en) | arsenic-IgM chelate as well as preparation method and application thereof | |
CN105004685B (en) | Mercury-IgE chelate and preparation method and application thereof | |
CN104987406A (en) | Nickel-IgA chelate as well as preparation method and application thereof | |
CN104987413A (en) | Arsenic-IgA chelate as well as preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151111 |
|
RJ01 | Rejection of invention patent application after publication |